PHK
PLRX icon

Point72 Hong Kong’s Pliant Therapeutics PLRX Stock Holding History

Point72 Hong Kong’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-804
Closed -$6K – 2305
2022
Q1 		$6K Sell
804
-413
-34% -$4.21K ﹤0.01% 1663
2021
Q4 		$16K Buy
+1,217
New +$19.3K ﹤0.01% 1579

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Point72 Hong Kong's PLRX Position: Q2 2022 in Review

Point72 Hong Kong sold out of Pliant Therapeutics (PLRX) in Q2 2022, closing a stake of 804 shares — an estimated $6K sold.

Point72 Hong Kong first reported a position in PLRX in Q4 2021 and held it in 2 quarters. The position peaked at $16K in Q4 2021. 88 funds tracked by Wall St. Rank hold PLRX as of Q2 2022.

  • Point72 Hong Kong reported no remaining Pliant Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 804 Pliant Therapeutics shares in Q2 2022, an estimated $6K.
  • Point72 Hong Kong first reported a position in Pliant Therapeutics in Q4 2021 and held it in 2 quarters.
  • Point72 Hong Kong's Pliant Therapeutics position peaked at $16K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.